Article
ARB/ACEI use and severe COVID-19: a nationwide case-control study
2020-06-13
Abstract excerpt
<h4>Summary</h4> <h4>Background</h4> Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) have anti-inflammatory effects. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the membrane protein angiotensin-converting enzyme 2 (ACE2), which is increased by ARB/ACEI treatment, as a cell entry receptor. Therefore, the use of ARBs/ACEIs for COVID-19 remains controver...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 843f8b77-6937-5f8d-97da-5e228b021e94
- DOI
- 10.1101/2020.06.12.20129916
